eyenovia-logo 3

News Releases

News Releases

11/10/21

On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022 Current cash resources anticipated to be sufficient to cover MydCombi NDA resubmission, completion of Phase 3 MicroLine program, and completion of
11/08/21

Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics NEW YORK , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of
11/05/21

Eyenovia will release third quarter 2021 results on Wednesday, November 10 , after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11 , after the close. Company to host an investor conference call and
11/04/21

Company to host an investor conference call and webcast at 5:00pm ET on that day NEW YORK , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company
11/04/21

Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone NEW YORK , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company
10/25/21

Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers Company received Complete Response Letter with additional requests and is preparing necessary documents for expedited resubmission NEW YORK , Oct.
08/11/21

Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia Company on track to initiate second Phase 3 presbyopia trial, VISION-2, by year-end 2021 MydCombi PDUFA date confirmed for October 28, 2021 Company to host conference call and
08/04/21

Company to host an investor conference call and webcast at 4:30pm ET on that day NEW YORK , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™)
07/19/21

Management team also provides investor updates at the Ladenburg Thalmann Healthcare Conference and “Lunch with LifeSci Featuring Eyenovia” events NEW YORK & LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Jul. 19, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company
07/07/21

NEW YORK , July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will present a corporate overview
06/15/21

NEW YORK , June 15, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today provided a corporate update on its pipeline with recent and upcoming milestones.
05/25/21

Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile Upcoming key 12 month milestones include Mydcombi PDUFA; Vision 2 Phase 3 trial results and completion of enrollment for CHAPERONE Phase 3 trial NEW YORK , May 25, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc.
05/12/21

MydCombi PDUFA date confirmed for October 28, 2021 Completed patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; top-line data on track for Q2 Secures $25 million credit facility through Silicon Valley Bank Company to host conference call and webcast
05/10/21

NEW YORK , May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a new $25 million credit financing facility with
05/05/21

Company to host an investor conference call and webcast at 4:30pm ET on that day NEW YORK , May 05, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc.  (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™)
04/01/21

NEW YORK --(BUSINESS WIRE)--Apr. 1, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and
03/25/21

Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 Company to host conference call and webcast today, March 25 , at 4:30 pm ET NEW YORK , March 25, 2021
03/23/21

NEW YORK & CHICAGO --(BUSINESS WIRE)--Mar. 23, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, and EVERSANA™ , the pioneer of next-generation
03/18/21

Company to host an investor conference call and webcast at 4:30pm ET on that day NEW YORK , March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc.  (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™)
03/17/21

NEW YORK --(BUSINESS WIRE)--Mar. 17, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the publication of “ Mydriasis with micro-array
03/10/21

NEW YORK , March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will participate in
03/02/21

PDUFA Date Expected 4Q 2021 NEW YORK --(BUSINESS WIRE)--Mar. 2, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S.
02/16/21

The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET NEW YORK , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a
01/26/21

Presentation Focuses on the Challenges and Biases Facing Presbyopia Patients, and Potential Benefits of Treatment Delivered with Eyenovia’s Novel Optejet® Dispenser NEW YORK --(BUSINESS WIRE)--Jan. 26, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company
01/06/21

NEW YORK , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc ., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, will